AGILENT TECHNOLOGIES (A) Company Report

Agilent’s Ignite transformation has shifted decision-making to an enterprise level, delivering procurement, pricing, and tariff mitigation wins, and broad organizational buy-in after six months of execution.
FY26 revenue growth is guided at 4–6%, underpinned by continued pharma recovery, stable China at ~$300 million per quarter, and expected 75 bps operating-margin expansion from pricing and volume leverage.
China performance ex-stimulus is seen as roughly flat at ~$300 million/qtr, with near-term quarterly swings due to Lunar New Year timing and consumables pull-ins, and potential stimulus late in the year.
The specialty CDMO segment (NASD + BioVectra) at $450–500 million revenue is growing mid-teens, with a 60/40 commercial/clinical mix, capacity expansions for siRNA, and GLP-1 volume tailwinds.
Agilent identifies a $1 billion digital/AI reshoring opportunity through 2030 (targeting ~30% share), and emphasizes disciplined capital allocation across internal growth, CDMO investments, M&A, and anti-dilutive share repurchases.

10 hours ago

Transcript

Agilent outlines FY25 transformation, 2026 guidance at Citi conference

Guidance Update

M&A

Agilent’s Ignite transformation has shifted decision-making from bottoms-up to an enterprise model, delivering early quick wins in strategic pricing and global procurement, regionalizing manufacturing to mitigate tariffs and improve customer value.
For 2026, Agilent targets 4–6% organic revenue growth driven by a pharma recovery and stable China sales (≈$300 million/quarter), with 75 bps of operating margin expansion plus upside to 90 bps; downside risks include SMID-cap biotech weakness and academic spending.
The specialty CDMO (NASD + BioVectra) business at $450–500 million of revenue was accretive to Agilent’s adjusted operating margin in 2025 and is expected to grow at mid-teens rates as new capacity (Train C/D) comes online.
Capital allocation prioritizes internal R&D, consumables and CDMO capacity, plus targeted M&A in software, automation and niche CDMO, underpinned by a more disciplined integration model via Ignite, alongside anti-dilutive share buybacks and dividends.

11 hours ago

Transcript

Agilent reports Q4 2025 results

Earnings

Guidance Update

Q4 revenue was $1.86 billion, up 7.2% core and 9.4% reported; diluted EPS of $1.59, a 9% YoY increase, both above guidance.
Broad-based growth: LC instrument sales grew low double-digit and LCMS mid-teens; specialty CDMO revenue rose over 40% core; PFAS business grew high single-digits.
Margins and cash generation strengthened: gross margin 54.1%, operating margin 27.2% (200 bps sequential expansion); operating cash flow of $545 million; share repurchases of $85 million, dividends of $70 million; net leverage 0.8x.
FY 2026 outlook: core revenue growth of 4–6% to $7.3–7.4 billion, EPS of $5.86–6.00, and 75 bps of operating margin expansion.

Nov 24, 2025, 9:30 PM

Transcript

Agilent announces Q4 2025 results

Earnings

Guidance Update

Q4 revenue of $1.86 billion (+7.2% core) and EPS of $1.59 (+9% yoy), both above guidance
Operating margin improved to 27.2% (+200 bps sequential) and gross margin to 54.1%, driven by Ignite pricing and tariff mitigation
FY 2026 guidance: $7.3–7.4 billion revenue (4–6% core growth), 75 bps operating margin expansion, EPS $5.86–6.00, and a 14.5% tax rate
Q4 capital deployment included $85 million share repurchases, $70 million dividends, $93 million CapEx; net leverage remained 0.8x
Segment performance: Life Sciences & Diagnostics +11%, Applied Markets +3%, CrossLab +6%; Americas & Europe +11%, China –4%, Asia ex-China +4%

Nov 24, 2025, 9:30 PM

Transcript

Agilent reports Q4 2025 results

Earnings

Guidance Update

M&A

Q4 revenue was $1.86 billion, with core growth of 7.2% and reported growth of 9.4%; Life Sciences & Diagnostics grew 11%, Applied Markets Group grew 3%, and CrossLab grew 6%.
Gross margin improved to 54.1% (+100 bps sequentially) and operating margin to 27.2% (+200 bps sequentially); EPS was $1.59, up 9% year-over-year.
FY 2026 guidance: revenue of $7.3 billion–$7.4 billion (core growth 4%–6%), 75 bps of operating margin expansion, and EPS of $5.86–$6.00 (+5%–7%).
Q4 operating cash flow was $545 million, with $93 million of CapEx, $85 million in share repurchases, $70 million in dividends (including a 3% dividend increase), and a 0.8x net leverage ratio.
The Ignite operating system delivered over $150 million in annualized savings and will fully mitigate current tariffs in FY 2026; integration of the BioVectra acquisition has been highly productive, bolstering CDMO capacity.

Nov 24, 2025, 9:30 PM

Transcript

Agilent Technologies reports strong Q4 profit growth, raises FY26 outlook

Earnings

Guidance Update

Agilent delivered Q4 profits of $434 million and revenues of $1.86 billion, a 9.4% year-over-year increase driven by robust life sciences and diagnostics demand.
For fiscal 2026, the company forecasts revenue of $7.3 billion–$7.4 billion and adjusted EPS of $5.86–$6.00.
Agilent’s fiscal Q1 guidance calls for revenue of $1.79 billion–$1.82 billion and adjusted EPS of $1.35–$1.38.
Segment growth in Q4 included 15% in life sciences & diagnostics, 7% in CrossLab and 4% in applied markets.

Nov 23, 2025, 11:07 PM

Morningstar

Agilent launches Insight Series alarm resolution systems

Product Launch

Agilent introduces Insight300M and InsightBLS next-generation liquid explosive detection systems for airport security, offering the industry’s lowest false alarm rate and rapid scan times.
The systems are fully software-upgradable to meet evolving global LAG screening regulations, eliminating the need for costly hardware reinvestment.
This launch represents a strategic expansion into the airport security market, building on Agilent’s 2017 acquisition of Cobalt Light Systems.
Agilent unveiled the new Insight Series at the International Security Expo in London, providing live demonstrations to security professionals and regulators.

Sep 30, 2025, 12:00 PM

Press Release

Agilent details Q3 performance and strategic initiatives

Product Launch

M&A

Strong Q3 driven by InfinityLab LC Series and 8850 GC replacement cycles, with 10% growth in chemical and advanced materials underpinned by new product launches and services execution.
Integration of BioVectra is on track, with completion of a production line reconfiguration in Q3 to boost 2026 capacity; NASD capacity for 2026 is fully booked, with new capacity online by late 2026/early 2027.
The three-year Ignite transformation has delivered $80 million in span-and-layer savings and $40 million in indirect procurement cost reductions, enabling digital and innovation investments.
China business remains stable and improving, targeting mid- to high-single-digit growth with an upcoming $140 million stimulus program opportunity.
Margins in Q3 were pressured by higher European tariffs, variable compensation accruals, and the BioVectra shutdown, but are expected to improve by 230 bps in Q4 as these headwinds normalize.

Sep 25, 2025, 8:50 AM

Transcript

Agilent reports strong Q3 growth and strategic outlook at Wells Fargo Healthcare Conference

Guidance Update

Revenue Acceleration/Inflection

Q3 FY25 core 6% revenue growth, broad-based across pharma, CAM and CDMO, prompting a 25% upgrade to the full-year revenue guide.
Tariffs in Q3 drove a 200 bp decline in gross margins; Agilent expects a 230 bp sequential margin rebound in Q4 and a net tailwind from tariff mitigations into 2026.
Early-innings replacement cycles: InfinityLab LC systems grew mid-teens and the new 8,850 GC is targeting a 10+-year installed base, with continued growth into 2026.
CDMO (NASD/BioVectra) posted 20% Q3 growth, with bookings well into 2026–27 and a shifting mix to ~50/50 clinical/commercial, driving long-term visibility.
China remains a stable $300 M/qtr market, with an estimated CN¥130–150 M stimulus funnel expected to materialize in calendar Q4–Q1.

Sep 3, 2025, 4:04 PM

Agilent reports Q3 2025 results and raises full-year guidance

Earnings

Guidance Update

Revenue Acceleration/Inflection

Delivered $1.74 B in Q3 revenue (+6.1% core) and $1.37 EPS, both above guidance.
Raised FY 2025 revenue outlook to $6.91–$6.93 B (≈4.5% core growth at midpoint), a $150 M increase from prior range.
Q4 revenue is expected at $1.82–$1.84 B (4.8–6.0% core growth) with ~230 bps sequential operating-margin improvement.
Ignite operating model drove double-digit cost savings, reduced management layers >15% and underpins full tariff mitigation in FY 2026.
Strong end-market performance: Pharma +9%, Chemicals & Advanced Materials +10%, Life Sciences & Diagnostics +7%, with broad geographic growth.

Aug 28, 2025, 9:38 PM

Earnings Transcripts

Quarterly earnings call transcripts for AGILENT TECHNOLOGIES.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Padraig McDonnell say about margins?What are AGILENT TECHNOLOGIES's strategic priorities?How is AGILENT TECHNOLOGIES positioned vs competitors?How did AGILENT TECHNOLOGIES do last quarter?

Let Fintool AI Agent track AGILENT TECHNOLOGIES's earnings for you

Get instant analysis when filings drop